RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $424
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Vertex Pharmaceuticals (VRTX) and raises the price target from $417 to $424.
May 07, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Vertex Pharmaceuticals and raises the price target from $417 to $424.
The increase in price target by RBC Capital suggests a positive outlook on Vertex Pharmaceuticals' stock value in the short term. This adjustment reflects an expectation of stronger performance or favorable market conditions for VRTX, likely leading to increased investor interest and potentially a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100